Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2015, Article ID 924131, 8 pages
http://dx.doi.org/10.1155/2015/924131
Research Article

PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia

1Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China
2Department of Cardiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

Received 24 August 2015; Accepted 30 September 2015

Academic Editor: Nguan Soon Tan

Copyright © 2015 Xiaomeng Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. UK Prospective Diabetes Study Group, “Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38,” British Medical Journal, vol. 317, no. 7160, pp. 703–713, 1998. View at Google Scholar
  2. H. N. Ginsberg, M. B. Elam, L. C. Lovato et al., “Effects of combination lipid therapy in type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 362, no. 17, pp. 1563–1574, 2010. View at Publisher · View at Google Scholar
  3. J.-C. Fruchart, F. M. Sacks, M. P. Hermans et al., “The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients,” Diabetes & Vascular Disease Research, vol. 5, no. 4, pp. 319–335, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C. P. Cannon, E. Braunwald, C. H. McCabe et al., “Intensive versus moderate lipid lowering with statins after acute coronary syndromes,” The New England Journal of Medicine, vol. 350, no. 15, pp. 1495–1504, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Lella and K. Indira, “A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia,” Journal of Advanced Pharmaceutical Technology and Research, vol. 4, no. 3, pp. 166–170, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. F. A. Monsalve, R. D. Pyarasani, F. Delgado-Lopez, and R. Moore-Carrasco, “Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases,” Mediators of Inflammation, vol. 2013, Article ID 549627, 18 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. S. J. Robins, D. Collins, J. T. Wittes et al., “Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial,” The Journal of the American Medical Association, vol. 285, no. 12, pp. 1585–1591, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Scott, R. O'Brien, G. Fulcher et al., “Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study,” Diabetes Care, vol. 32, no. 3, pp. 493–498, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Belfort, R. Berria, J. Cornell, and K. Cusi, “Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 2, pp. 829–836, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Wang, L. He, J. Liu et al., “Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia,” Cardiovascular Therapeutics, vol. 31, no. 3, pp. 161–167, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Liu, C. Lu, F. Li et al., “PPAR-α agonist fenofibrate upregulates tetrahydrobiopterin level through increasing the expression of Guanosine 5′-triphosphate cyclohydrolase-I in human umbilical vein endothelial cells,” PPAR Research, vol. 2011, Article ID 523520, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Boström, J. Wu, M. P. Jedrychowski et al., “A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis,” Nature, vol. 481, no. 7382, pp. 463–468, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Xiang, G. Xiang, L. Yue, J. Zhang, and L. Zhao, “Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy,” Atherosclerosis, vol. 235, no. 2, pp. 328–333, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Sesti, F. Andreozzi, T. V. Fiorentino et al., “High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects,” Acta Diabetologica, vol. 51, no. 5, pp. 705–713, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. K. N. Aronis, M. Moreno, S. A. Polyzos et al., “Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events,” International Journal of Obesity, vol. 39, no. 1, pp. 156–161, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Aydin, T. Kuloglu, S. Aydin et al., “Irisin: a potentially candidate marker for myocardial infarction,” Peptides, vol. 55, pp. 85–91, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Aydin, S. Aydin, M. A. Kobat et al., “Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology,” Peptides, vol. 56, pp. 141–145, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. J. I. Castillo-Quan, “From white to brown fat through the PGC-1alpha dependent myokine irisin: implications for diabetes and obesity,” Disease Models and Mechanisms, vol. 5, no. 3, pp. 293–295, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. B. K. Pedersen and M. A. Febbraio, “Muscle as an endocrine organ: focus on muscle-derived interleukin-6,” Physiological Reviews, vol. 88, no. 4, pp. 1379–1406, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. J.-J. Liu, M. D. S. Wong, W. C. Toy et al., “Lower circulating irisin is associated with type 2 diabetes mellitus,” Journal of Diabetes and Its Complications, vol. 27, no. 4, pp. 365–369, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. Y.-K. Choi, M.-K. Kim, K. H. Bae et al., “Serum irisin levels in new-onset type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 100, no. 1, pp. 96–101, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. K. H. Park, L. Zaichenko, M. Brinkoetter et al., “Circulating irisin in relation to insulin resistance and the metabolic syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 12, pp. 4899–4907, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Li, M. Yang, X. Zhou et al., “Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 4, pp. 1485–1493, 2015. View at Publisher · View at Google Scholar
  25. P. A. Boström and J. M. Fernández-Real, “Metabolism: irisin, the metabolic syndrome and follistatin in humans,” Nature Reviews Endocrinology, vol. 10, no. 1, pp. 11–12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Y. Huh, G. Panagiotou, V. Mougios et al., “FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise,” Metabolism: Clinical and Experimental, vol. 61, no. 12, pp. 1725–1738, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. N. M. Al-Daghri, K. M. Alkharfy, S. Rahman et al., “Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects,” European Journal of Clinical Investigation, vol. 44, no. 2, pp. 119–124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Panagiotou, L. Mu, B. Na, K. J. Mukamal, and C. S. Mantzoros, “Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk,” Metabolism, vol. 63, no. 10, pp. 1265–1271, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. B. P. Neve, J.-C. Fruchart, and B. Staels, “Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis,” Biochemical Pharmacology, vol. 60, no. 8, pp. 1245–1250, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. T. L. Rachid, A. Penna-de-Carvalho, I. Bringhenti, M. B. Aguila, C. A. Mandarim-de-Lacerda, and V. Souza-Mello, “Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice,” Molecular and Cellular Endocrinology, vol. 402, pp. 86–94, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. E. H. Koh, M.-S. Kim, J.-Y. Park et al., “Peroxisome proliferator-activated receptor (PPAR)-α activation prevents diabetes in OLETF rats: comparison with PPAR-γ activation,” Diabetes, vol. 52, no. 9, pp. 2331–2337, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. C. W. Park, Y. Zhang, X. Zhang et al., “PPARα agonist fenofibrate improves diabetic nephropathy in db/db mic,” Kidney International, vol. 69, no. 9, pp. 1511–1517, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. G. M. Keating, “Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus,” American Journal of Cardiovascular Drugs, vol. 11, no. 4, pp. 227–247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Hennuyer, A. Tailleux, G. Torpier et al., “PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1897–1902, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Gervois, R. Kleemann, A. Pilon et al., “Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-α activator fenofibrate,” The Journal of Biological Chemistry, vol. 279, no. 16, pp. 16154–16160, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Kowalski, B. Okopien, A. Madej et al., “Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia,” International Journal of Clinical Pharmacology and Therapeutics, vol. 41, no. 6, pp. 241–247, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. M. A. Yakubu, R. H. Nsaif, and A. O. Oyekan, “Peroxisome proliferator-activated receptor α activation-mediated regulation of endothelin-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture,” Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 2, pp. 774–781, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. T.-L. Yue, W. Bao, B. M. Jucker et al., “Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injur,” Circulation, vol. 108, no. 19, pp. 2393–2399, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Ibarra-Lara, E. Hong, E. Soria-Castro et al., “Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia,” Journal of Cardiovascular Pharmacology, vol. 60, no. 4, pp. 323–334, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Albrecht, F. Norheim, B. Thiede et al., “Irisin—a myth rather than an exercise-inducible myokine,” Scientific Reports, vol. 5, article 8889, 2015. View at Publisher · View at Google Scholar
  41. T. Kurdiova, M. Balaz, M. Vician et al., “Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: In vivo and in vitro studies,” Journal of Physiology, vol. 592, no. 5, pp. 1091–1107, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. H.-H. Wang, X.-W. Zhang, W.-K. Chen, Q.-X. Huang, and Q.-Q. Chen, “Relationship between serum irisin levels and urinary albumin excretion in patients with type 2 diabetes,” Journal of Diabetes and its Complications, vol. 29, no. 3, pp. 384–389, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Zhang, P. Chen, S. Chen et al., “The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study,” European Review for Medical and Pharmacological Sciences, vol. 18, no. 11, pp. 1567–1572, 2014. View at Google Scholar
  44. C. Moraes, V. O. Leal, S. M. Marinho et al., “Resistance exercise training does not affect plasma irisin levels of hemodialysis patients,” Hormone and Metabolic Research, vol. 45, no. 12, pp. 900–904, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. R. R. Kraemer, P. Shockett, N. D. Webb, U. Shah, and V. D. Castracane, “A transient elevated irisin blood concentration in response to prolonged, moderate aerobic exercise in young men and women,” Hormone and Metabolic Research, vol. 46, no. 2, pp. 150–154, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. M. P. Jedrychowski, C. D. Wrann, J. A. Paulo et al., “Detection and quantitation of circulating human irisin by tandem mass spectrometry,” Cell Metabolism, vol. 22, no. 4, pp. 734–740, 2015. View at Publisher · View at Google Scholar